Research Article

Faktor risiko yang mempengaruhi length of stay pasien kanker solid dengan febrile neutropenia pasca kemoterapi neoadjuvant/terapeutik di Ruang Isolasi RSUP Sanglah, Bali

Ronald Natawidjaja , Ida Bagus Tjakra Wibawa Manuaba, Putu Anda Tusta Adiputra

Ronald Natawidjaja
Residen Bedah Umum, Universitas Udayana- RSUP Sanglah, Bali. Email: ronaldnatawidjaja@gmail.com

Ida Bagus Tjakra Wibawa Manuaba
Staf Pengajar Departemen Bedah Onkologi, Fakultas Kedokteran Universitas Udayana – RSUP Sanglah, Bali - Indonesia

Putu Anda Tusta Adiputra
Staf Pengajar Departemen Bedah Onkologi, Fakultas Kedokteran Universitas Udayana – RSUP Sanglah, Bali - Indonesia
Online First: April 01, 2019 | Cite this Article
Natawidjaja, R., Manuaba, I., Adiputra, P. 2019. Faktor risiko yang mempengaruhi length of stay pasien kanker solid dengan febrile neutropenia pasca kemoterapi neoadjuvant/terapeutik di Ruang Isolasi RSUP Sanglah, Bali. Intisari Sains Medis 10(1). DOI:10.15562/ism.v10i1.367


Background. Febrile neutropenia is a common complication in patient undergoing chemotherapy. Length Of Stay (LOS) is an important marker for disease severity and use of medical resources in febrile neutropenia. This study was done to find the risk factor affecting length of stay in solid cancer patients with febrile neutropenia post neoadjuvant/therapeutic chemotherapy.

Method. This is a case control study without matching. Age ≥ 60 years, (Absolute Neutrofil Count) ANC level < 1,5 μL , comorbid,  Hb level <10 gr/dl, and albumin < 3 gr/dl, were related to LOS ( ≤ 5 days and > 5 days). Univariate (chi square) and multivariate (logistic regression) were used to analyse the statistic.

Results. Forty six patients met inclusion-exclusion criteria were included in this study. ANC level in all patients were < 1,5 μL (100%). Hb level <10 gr/dl is statistically significant (P<0.05), whereas  age ≥ 60 years, and comorbid, albumin level < 3 gr/dl were not is statistically significant (P>0.05).

Conclusion. Hb level < 10 gr/dl is the risk factor for LOS > 5 days in solid cancer patients with febrile neutropenia post neoadjuvant/therapeutic chemotherapy.

References

Mohamed I. Carcinoma of the Breast. In: Skeel RT (ed) Handbook of Cancer Chemotherapy. 7th ed. Philadelpia: Lippincott Williams & Wilkins. 2007: 298-321.

Yarso K, Sudarsa I, Wibawa-Manuaba I. Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study). Bali Medical Journal. 2012; 1(1):12-16.

Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H., Lyman G.H. 2015. Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors. American Society of Clinical Oncology: Journal of Oncology Practice. 2015; 11(1): 47-56.

Dulisse B, Li SX, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA.. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ. 2013; 16(6): 720–735.

Summerhayes M, Daniel S. Practical Chemotherapy. Bristol: Radchiffe Medical Press. 2003: 45-65.

Schimpff SC. Empiric antibiotic therapy for granulocytopenic patients. Bull N Y Acad Med. 1982; 58(8): 750–756.

Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leucocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64(2):328-340.

Schilling MB, Parks C, Deeter RG. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study. Exp Ther Med. 2011; 2(5): 859–866.

Zhou YP, Jin J, Ding Y, Chee YL, Koh LP, Chng WJ, Chan DS, Hsu LY. Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore. Support Care Cancer. 2014; 22(6):1447-51.

Silber JH. Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood count and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol. 1998; 16(7): 2392-2400.

Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M; OPPS Working Group; ANC Study Group.. Risk of Febrile Neutropenia among Patients with Intermediate-Grade Non-Hodgkin’s Lymphoma Receiving CHOP Chemotherapy. Leuk Lymphoma. 2003; 44(12):2069-276.

Morrison V.A., Caggiano V., Fridman M. A Model to Predict Chemotherapy-Related Severe or Febrile Neutropenia in Cycle One among Breast Cancer and Lymphoma Patients. Proc Am Soc Clin Oncol, 2004; 23:742.

Kloess M, Wunderlich A, Trumper L. Predicting hematotoxicity in multicycle chemotherapy. Blood. 1999; 94 (suppl 1):87a.

Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA.. The Predictive Value of Body Protein for Chemotherapy-Induced Toxicity. Cancer. 2000; 88(4): 796-803

Saleem L, Zahid NA. Is Serum Albumin an Independent Predictor of Post Chemotherapy Febrile Neutropenia? Pak Armed Forces Med J: Pakistan. 2017; 67(5):768-74

Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C, Monneret G, Gutowski MC, Coiffier B, Salles G.Factors that predict chemotherapy-induced myelosuppresion in lymhoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol. 2000; 18(2):325-31.

Gonzalez-Barca E, Sevilla AF, Carratala J, Salar A, Peris J, Grañena A, Gudiol F. Prognostic factor influencing mortality in cancer patients with neutropenia and bacteremia. Eur J Clin Microbiol Infect Dis. 1999; 18(8):539-44.

Kuderer N, Cosler LE, Crawford J, Dale DC, Lyman GH. Cost and mortality associated with febrile neutropenia in adult patients. Proc Am Soc Clin Oncol. 2002; 21:250.

Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J.. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low risk febrile neutropenic cancer patients. J Clin Oncol. 2000; 18(16):3038-3051.

Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, Budiana ING, Manuaba IBAP. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pacific Journal of Cancer Prevention. 2019; 20(3).


No Supplementary Material available for this article.
Article Views      : 53
PDF Downloads : 29